US › Healthcare

Immatics NV (IMTX)

US · Healthcare · Biotechnology

$8.82+2.08%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$9.1M

Revenue YoY

+93.0%

Net profit

$-62.5M

EPS

$-0.53

EPS estimate

$-0.43

Net margin

-683.4%

EPS came in at -0.53 against a street estimate of -0.43 — a miss of 23.3%.

Key statistics

Market cap

$1.34B

Forward P/E

0.0

P/B

2.88

Book value

$3.39

EPS (TTM)

$-1.85

52-week high

$12.41

52-week low

$5.67

50-day MA

$9.35

200-day MA

$9.99

Beta

1.33

Analyst view

Analysts rate Immatics NV a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $17.63.

Shareholding

Insiders

15.78%

Institutions

66.66%

Largest institutional holders

Fund	Stake
T. Rowe Price Investment Management,Inc.	15.84%
RTW INVESTMENTS, LLC	9.41%
Suvretta Capital Management, LLC	8.19%
Baker Bros Advisors LP	7.99%
Perceptive Advisors LLC	7.60%
The Toronto-Dominion Bank	5.44%
Vestal Point Capital LP	4.52%
Jefferies Financial Group Inc	3.70%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Immatics NV — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.